16-30 of 72
Managing Adverse Events Associated With Menin Inhibitors
MinuteCE®Managing Adverse Events Associated With Menin Inhibitors
Ghayas Issa, MD
Amir Fathi, MD
Ghayas Issa, MD
Amir Fathi, MD
Emerging Directions in Menin-Directed AML Therapy
MinuteCE®Emerging Directions in Menin-Directed AML Therapy
Ghayas Issa, MD
Amir Fathi, MD
Ongoing Clinical Trials in AML With Menin Inhibitors
MinuteCE®Ongoing Clinical Trials in AML With Menin Inhibitors
Ghayas Issa, MD
Amir Fathi, MD
Ghayas Issa, MD
Amir Fathi, MD
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
- advertisement
Differential Diagnosis of Indolent Systemic Mastocytosis
MinuteCE®Differential Diagnosis of Indolent Systemic Mastocytosis
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
Diagnosis and Treatment of Systemic Mastocytosis With an Associated Hematologic Neoplasm
MinuteCE®Diagnosis and Treatment of Systemic Mastocytosis With an Associated Hematologic Neoplasm
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
Accurate Diagnosis and Management of Hereditary Alpha Tryptasemia
MinuteCE®Accurate Diagnosis and Management of Hereditary Alpha Tryptasemia
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
Guideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitor
MinuteCE®Guideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitor
Seema A. Bhat, MD
Jeremy S. Abramson, MD, MMSc
Clinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapies
MinuteCE®Clinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapies
Seema A. Bhat, MD
Jeremy S. Abramson, MD, MMSc
- advertisement
Incorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapy
MinuteCE®Incorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapy
Seema A. Bhat, MD
Jeremy S. Abramson, MD, MMSc
Emerging data with potentially guideline-changing implications in CLL/SLL and MCL
MinuteCE®Emerging data with potentially guideline-changing implications in CLL/SLL and MCL
Seema A. Bhat, MD
Jeremy S. Abramson, MD, MMSc
Ignacio Duran, MD
Wenxin Xu, MD
Sandy Srinivas, MD
